表紙
市場調査レポート

癌の新しい治療薬:パイプライン最終段階を占めるプロテインキナーゼ阻害剤・モノクローナル抗体・ワクチン治療クラス

Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

発行 GBI Research 商品コード 246718
出版日 ページ情報 英文 172 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
癌の新しい治療薬:パイプライン最終段階を占めるプロテインキナーゼ阻害剤・モノクローナル抗体・ワクチン治療クラス Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline
出版日: 2012年07月10日 ページ情報: 英文 172 Pages
概要

少数の標的集団に特に効果を発揮する治療薬への当局による承認が進む中で、癌治療はますます個別化が進んでいます。非小細胞肺癌患者全体のわずか5%に効果があるPfizer社Xalkori(クリゾチニブ)の承認や大腸癌患者におけるアービタックスの適応範囲の限定は、癌治療の焦点がパーソナル化へと移行していることを示しています。

当レポートでは、8種の癌に対するパイプラインの動向について調査分析し、癌治療に利用される主な上市薬、開発中の主な薬剤クラス、新しい治療薬の市場機会とアンメットニーズ、フェーズおよび癌の種類別のパイプライン動向、有望視されている分子標的薬、企業間のM&A、各種契約動向などをまとめ、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 主なイノベーション・技術

  • イントロダクション
    • 癌の増加
    • 癌のリスク因子
  • 癌治療の経路
    • 化学療法
    • 標的治療
  • 癌治療の主な上市薬
    • リツキサン/MabThera
    • ハーセプチン
    • グリベック
    • アバスチン
    • エロキサチン
    • アービタックス
    • ゼローダ
    • フェマラ
    • テモダール
    • タルセバ
    • タキソテレ
    • レブラミド
    • アリムタ

第4章 将来の新しい薬剤クラス

  • プロテインキナーゼ阻害剤
  • ワクチン
    • 腫瘍細胞ワクチン
    • 腫瘍抗原ワクチン
    • 樹状細胞ワクチン
    • 抗イディオタイプワクチン

第5章 市場機会とアンメットニーズの分析

  • 乳癌
  • 大腸癌
  • NHL
  • NSCLC
  • 前立腺癌
  • 卵巣
  • 子宮頸癌
  • 頭頚部癌

第6章 製品パイプライン分析

  • イントロダクション
  • 乳癌
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • 新薬発見
    • フェーズI
    • フェーズII
    • フェーズIII
    • NDA申請済み
  • 大腸癌
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • 新薬発見
    • フェーズI
    • フェーズII
    • フェーズIII
  • NHL
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • 新薬発見
    • フェーズI
    • フェーズII
    • フェーズIII
    • NDA申請済み
  • NSCLC
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • 新薬発見
    • フェーズI
    • フェーズII
    • フェーズIII
    • NDA申請済み
  • 前立腺癌
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • 新薬発見
    • フェーズI
    • フェーズII
    • フェーズIII
    • NDA申請済み
  • 子宮癌
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • 新薬発見
    • フェーズI
    • フェーズII
    • フェーズIII
    • NDA申請済み
  • 子宮頸癌
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • フェーズI
    • フェーズII
    • フェーズIII
  • 頭頚部癌
    • イントロダクション
    • 治療クラス別分析
    • 前臨床
    • 新薬発見
    • フェーズI
    • フェーズII
    • フェーズIII

第7章 将来有望な分子標的薬

  • T-DM1
  • アフィニトール(everolimus)
  • Iniparib(E75)
  • Afatinib
  • アバスチン
  • Farletuzumab
  • V503
  • タイケルブ
  • TheraCIM
    • イントロダクション
    • 作用機序
    • 収益

第8章 戦略的統合

  • M&A環境
  • R&Dライセンシング契約
  • 共同開発契約

第9章 付録

図表一覧

目次

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline" which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

GBI Research also analyzed the promising pipeline molecules that are expected to be launched during the forecast period (2012-2018). The molecules are Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM. The launch of promising molecules is projected to add $2,979m in revenues by 2018. The novel molecules are expected to increase progression free survival, providing a better treatment option to cancer patients. The molecules are expected to address the safety and unmet needs. GBI Research analyzed 63 M&A deals, 95 licensing deals and 67 R&D collaboration agreements that took place during 2007-2011 and found that competitive activity is increasing in the oncology therapeutics market.

Scope

  • Data and analysis on the leading therapeutic classes in oncology.
  • Market data on the promising molecules in the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer.
  • Key M&A activities and licensing agreements that took place from 2005-2011 in the oncology market.

Reasons to buy

  • Align your product portfolio to markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Executive Summary

Tailor-Made Treatments in Oncology to Dominate Future Therapy.

Cancer treatments are becoming increasingly personalized, as regulators are approving therapeutics offering significant benefits to small target populations, according to a new report by healthcare experts GBI Research.

The new report* states that although therapeutic options that target a small population are expensive, their uptake is expected to be rapid in the target population.

The approval of Pfizer's Xalkori (crizotinib), which treats only 5% of the total Non-Small Cell Lung Cancer (NSCLC) patient population, and the change in Erbitux's coverage of the colorectal cancer patient population (from every patient to wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) patients) indicates a shift in focus to more personalized cancer treatment.

The launch of novel pipeline molecules such as Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM, is projected to add $2,979m in revenue by 2018. These novel molecules are expected to be launched during the next six years, and are expected to increase progression-free survival, therefore promising a better life to many cancer patients. The molecules are also expected to address the safety and unmet needs of various cancer treatments for breast cancer, ovarian cancer, cervical cancer, NSCLC and Non-Hodgkin's Lymphoma (NHL).

The development pipeline contains targeted therapeutics in Phase III, which are expected to be launched during the next few years to drive growth in the oncology market. Pipeline drugs include protein kinase inhibitors, monoclonal antibodies and vaccines, with a total of 1,198 molecules under investigation.

The protein kinase inhibitor has the highest number of molecules under development, accounting for 42% of the oncology pipeline, with 194 monoclonal antibody molecules in development and 63 vaccine molecules in various stages of development. Protein kinase inhibitors are one of the major classes under development, due to the role of this protein in helping cancer cells evade normal physiological constraints on growth and survival.

Monoclonal antibodies such as Avastin (bevacizumab), Erbitux (cetuximab), Rituxan (rituximab) and Herceptin (trastuzumab) also represent a leading class of drugs in the oncology therapeutics market. These are safer and more effective than the conventional chemotherapy treatment options, and target the unmet needs of late-stage cancer patients, having proven successful in improving survival and quality of life. The number of monoclonal antibodies in the drug development pipeline for the treatment of cancer increased over the last decade, driven by their own success, but they are therefore priced at a premium.

GBI Research predicts that novel therapies will generate revenue of $2,979m by 2018 for the oncology therapeutics market, which will grow at a CAGR of 113% during 2012-2018.

Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline

This report provides in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Novel Therapies in Oncology - Introduction

3. Novel Therapies in Oncology - Key Innovations and Technologies

  • 3.1. Introduction
    • 3.1.1. Increase in Cancer
    • 3.1.2. Risk Factors for Cancer
  • 3.2. Oncology Treatment Pathways
    • 3.2.1. Chemotherapeutics
    • 3.2.2. Targeted Therapies
  • 3.3. Leading Marketed Drugs in Oncology
    • 3.3.1. Rituxan/ MabThera
    • 3.3.2. Herceptin
    • 3.3.3. Gleevec/Glivec
    • 3.3.4. Avastin
    • 3.3.5. Eloxatin
    • 3.3.6. Erbitux
    • 3.3.7. Xeloda
    • 3.3.8. Femara
    • 3.3.9. Temodar
    • 3.3.10. Tarceva
    • 3.3.11. Taxotere
    • 3.3.12. Revlimid
    • 3.3.13. Alimta

4. Novel Therapies in Oncology - Leading Novel Drug Classes for the Future

  • 4.1. Protein Kinase Inhibitors
  • 4.2. Vaccines
    • 4.2.1. Tumor Cell Vaccines
    • 4.2.2. Antigen Vaccines
    • 4.2.3. Dendritic Cell Vaccines
    • 4.2.4. Anti-Idiotype vaccines

5. Novel Therapies in Oncology - Opportunity and Unmet Need Analysis

  • 5.1. Breast Cancer
  • 5.2. Colorectal Cancer
  • 5.3. NHL
  • 5.4. NSCLC
  • 5.5. Prostate Cancer
  • 5.6. Ovarian Cancer
  • 5.7. Cervical Cancer
  • 5.8. Head and Neck Cancer

6. Novel Therapies in Oncology - Product Pipeline Analysis

  • 6.1. Introduction
  • 6.2. Breast Cancer
    • 6.2.1. Breast Cancer Pipeline - Introduction
    • 6.2.2. Breast Cancer Pipeline - Analysis by Therapeutic Class
    • 6.2.3. Breast Cancer Pipeline - Pre-Clinical
    • 6.2.4. Breast Cancer Pipeline - Discovery
    • 6.2.5. Breast Cancer Pipeline - Phase I
    • 6.2.6. Breast Cancer Pipeline - Phase II
    • 6.2.7. Breast Cancer Pipeline - Phase III
    • 6.2.8. Breast Cancer Pipeline - NDA Filed
  • 6.3. Colorectal Cancer
    • 6.3.1. Colorectal Cancer Pipeline - Introduction
    • 6.3.2. Colorectal Cancer Pipeline - Analysis by Therapeutic Class
    • 6.3.3. Colorectal Cancer Pipeline - Pre-Clinical
    • 6.3.4. Colorectal Cancer Pipeline - Discovery
    • 6.3.5. Colorectal Cancer Pipeline - Phase I
    • 6.3.6. Colorectal Cancer Pipeline - Phase II
    • 6.3.7. Colorectal Cancer Pipeline - Phase III
  • 6.4. NHL
    • 6.4.1. NHL Pipeline - Introduction
    • 6.4.2. NHL Pipeline - Analysis by Therapeutic Class
    • 6.4.3. NHL Pipeline - Pre-Clinical
    • 6.4.4. NHL Pipeline - Discovery
    • 6.4.5. NHL Pipeline - Phase I
    • 6.4.6. NHL Pipeline - Phase II
    • 6.4.7. NHL Pipeline - Phase III
    • 6.4.8. NHL Pipeline - NDA Filed
  • 6.5. NSCLC
    • 6.5.1. NSCLC Pipeline - Introduction
    • 6.5.2. NSCLC Pipeline - Analysis by Therapeutic Class
    • 6.5.3. NSCLC Pipeline - Pre-Clinical
    • 6.5.4. NSCLC Pipeline - Discovery
    • 6.5.5. NSCLC Pipeline - Phase I
    • 6.5.6. NSCLC Pipeline - Phase II
    • 6.5.7. NSCLC Pipeline - Phase III
    • 6.5.8. NSCLC Pipeline - NDA Filed
  • 6.6. Prostate Cancer
    • 6.6.1. Prostate Cancer Pipeline - Introduction
    • 6.6.2. Prostate Cancer Pipeline - Analysis by Therapeutic Class
    • 6.6.3. Prostate Cancer Pipeline - Pre-Clinical
    • 6.6.4. Prostate Cancer Pipeline - Discovery
    • 6.6.5. Prostate Cancer Pipeline - Phase I
    • 6.6.6. Prostate Cancer Pipeline - Phase II
    • 6.6.7. Prostate Cancer Pipeline - Phase III
    • 6.6.8. Prostate Cancer Pipeline - NDA Filed
  • 6.7. Ovarian Cancer
    • 6.7.1. Ovarian Cancer Pipeline - Introduction
    • 6.7.2. Ovarian Cancer Pipeline - Analysis by Therapeutic Class
    • 6.7.3. Ovarian Cancer Pipeline - Pre-Clinical
    • 6.7.4. Ovarian Cancer Pipeline - Discovery
    • 6.7.5. Ovarian Cancer Pipeline - Phase I
    • 6.7.6. Ovarian Cancer Pipeline - Phase II
    • 6.7.7. Ovarian Cancer Pipeline - Phase III
    • 6.7.8. Ovarian Cancer Pipeline - NDA Filed
  • 6.8. Cervical Cancer
    • 6.8.1. Cervical Cancer Pipeline - Introduction
    • 6.8.2. Cervical Cancer Pipeline - Analysis by Therapeutic Class
    • 6.8.3. Cervical Cancer Pipeline - Pre-Clinical
    • 6.8.4. Cervical Cancer Pipeline - Phase I
    • 6.8.5. Cervical Cancer Pipeline - Phase II
    • 6.8.6. Cervical Cancer Pipeline - Phase III
  • 6.9. Head and Neck Cancer
    • 6.9.1. Head and Neck Cancer Pipeline - Introduction
    • 6.9.2. Head and Neck Cancer Pipeline - Analysis by Therapeutic Class
    • 6.9.3. Head and Neck Cancer Pipeline - Pre-Clinical
    • 6.9.4. Head and Neck Cancer Pipeline - Discovery
    • 6.9.5. Head and Neck Cancer Pipeline - Phase I
    • 6.9.6. Head and Neck Cancer Pipeline - Phase II
    • 6.9.7. Head and Neck Cancer Pipeline - Phase III

7. Novel Therapies In Oncology - Promising Molecules

  • 7.1. T-DM1
    • 7.1.1. Introduction
    • 7.1.2. Mechanism of Action
    • 7.1.3. Revenues
  • 7.2. Afinitor (everolimus)
    • 7.2.1. Introduction
    • 7.2.2. Mechanism of Action
    • 7.2.3. Revenues
  • 7.3. Iniparib (E75)
    • 7.3.1. Introduction
    • 7.3.2. Mechanism of Action
    • 7.3.3. Revenues
  • 7.4. Afatinib
    • 7.4.1. Introduction
    • 7.4.2. Mechanism of Action
    • 7.4.3. Revenues
  • 7.5. Avastin
    • 7.5.1. Introduction
    • 7.5.2. Mechanism of Action
    • 7.5.3. Revenues
  • 7.6. Farletuzumab
    • 7.6.1. Introduction
    • 7.6.2. Mechanism of Action
    • 7.6.3. Revenues
  • 7.7. V503
    • 7.7.1. Introduction
    • 7.7.2. Mechanism of Action
    • 7.7.3. Revenues
  • 7.8. Tykerb
    • 7.8.1. Introduction
    • 7.8.2. Mechanism of Action
    • 7.8.3. Revenues
  • 7.9. TheraCIM
    • 7.9.1. Introduction
    • 7.9.2. Mechanism of Action
    • 7.9.3. Revenues

8. Novel Therapies In Oncology - Strategic Consolidations

  • 8.1. M&A Landscape
    • 8.1.1. M&A Deals by Year
    • 8.1.2. M&A Deals by Geography
    • 8.1.3. M&A Deals by Value
    • 8.1.4. M&A Deals by Deal Type
  • 8.2. R&D Licensing Agreements
    • 8.2.1. Deals by Year
    • 8.2.2. Deals by Geography
    • 8.2.3. Deals by Value
  • 8.3. Co-Development Agreements
    • 8.3.1. Deals by Year
    • 8.3.2. Deals by Geography
    • 8.3.3. Deals by Value

9. Novel Therapies In Oncology - Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Sources
  • 9.4. Research Methodology
    • 9.4.1. Coverage
    • 9.4.2. Secondary Research
    • 9.4.3. Primary Research
    • 9.4.4. Section Wise Methodology
    • 9.4.5. Expert Panel Validation
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Novel Therapies in Oncology, Oncology Clinical Trials, 2011
  • Table 2: Novel Therapies in Oncology, Pipeline by Developmental Phase, 2011
  • Table 3: Novel Therapies in Oncology, Pipeline by Indication, 2011
  • Table 4: Novel Therapies in Oncology, Pipeline by Therapeutic Class, 2011
  • Table 5: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase, 2011
  • Table 6: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 7: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011
  • Table 8: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011
  • Table 9: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 10: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 11: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 12: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Stage Molecules, 2011
  • Table 13: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules, 2011
  • Table 14: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules, 2011
  • Table 15: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules, 2011
  • Table 16: Novel Therapies in Oncology, Breast Cancer Pipeline, NDA Filed Molecules, 2011
  • Table 17: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase, 2011
  • Table 18: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 19: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011
  • Table 20: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class , 2011
  • Table 21: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 22: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 23: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Stage Molecules, 2011
  • Table 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules, 2011
  • Table 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules, 2011
  • Table 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules, 2011
  • Table 28: Novel Therapies in Oncology, NHL Pipeline by Phase, 2011
  • Table 29: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 30: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class, 2011
  • Table 31: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class, 2011
  • Table 32: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 33: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 34: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 35: Novel Therapies in Oncology, NHL Pipeline, Discovery Stage Molecules, 2011
  • Table 36: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules, 2011
  • Table 37: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules, 2011
  • Table 38: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules, 2011
  • Table 39: Novel Therapies in Oncology, NHL Pipeline, NDA Filed Molecules, 2011
  • Table 40: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase, 2011
  • Table 41: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 42: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class, 2011
  • Table 43: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class, 2011
  • Table 44: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 45: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 46: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class, 2011
  • Table 47: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 48: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Stage Molecules, 2011
  • Table 49: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules, 2011
  • Table 50: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules, 2011
  • Table 51: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules, 2011
  • Table 52: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules, 2011
  • Table 53: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase, 2011
  • Table 54: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 55: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011
  • Table 56: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 57: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 58: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class, 2011
  • Table 59: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 60: Novel Therapies in Oncology, Prostate Cancer Pipeline, Discovery Stage Molecules, 2011
  • Table 61: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules, 2011
  • Table 62: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules, 2011
  • Table 63: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules, 2011
  • Table 64: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules, 2011
  • Table 65: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase, 2011
  • Table 66: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 67: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class,2011
  • Table 68: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 69: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 70: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 71: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Discovery Stage Molecules, 2011
  • Table 72: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules, 2011
  • Table 73: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules, 2011
  • Table 74: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011
  • Table 75: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules, 2011
  • Table 76: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase, 2011
  • Table 77: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 78: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011
  • Table 79: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 80: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 81: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 82: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules, 2011
  • Table 83: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules, 2011
  • Table 84: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules, 2011
  • Table 85: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase, 2011
  • Table 86: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class, 2011
  • Table 87: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Molecules by Therapeutic Class, 2011
  • Table 88: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class, 2011
  • Table 89: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class, 2011
  • Table 90: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class, 2011
  • Table 91: Novel Therapies in Oncology, Head And Neck Cancer Pipeline, Pre-Clinical Stage Molecules, 2011
  • Table 92: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Discovery Stage Molecules, 2011
  • Table 93: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules, 2011
  • Table 94: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules, 2011
  • Table 95: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules, 2011
  • Table 96: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018
  • Table 97: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018
  • Table 98: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018
  • Table 99: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018
  • Table 100: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018
  • Table 101: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2015-2018
  • Table 102: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018
  • Table 103: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018
  • Table 104: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018
  • Table 105: Novel Therapies in Oncology, Global, Major M&A Deals, 2007-2011
  • Table 106: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011
  • Table 107: Novel Therapies in Oncology, Global, M&A Deals by Geography, 2007-2011
  • Table 108: Novel Therapies in Oncology, Global, M&A Deals by Value, 2007-2011
  • Table 109: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, 2007-2011
  • Table 110: Novel Therapies in Oncology, Global, Major R&D Licensing Deals, 2007-2011
  • Table 111: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011
  • Table 112: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, 2007-2011
  • Table 113: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, 2007-2011
  • Table 114: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011
  • Table 115: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011
  • Table 116: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, 2007-2011
  • Table 117: Novel Therapies in Oncology, Global, Co-Development Deals by Value, 2007-2011

List of Figures

  • Figure 1: Novel Therapies in Oncology, Oncology Clinical Trials Share (%), 2011
  • Figure 2: Novel Therapies in Oncology, Protein Kinase Inhibitors Molecules by Indication, 2011
  • Figure 3: Novel Therapies in Oncology, Vaccine Molecules by Indication, 2011
  • Figure 4: Novel Therapies in Oncology, Metastatic Breast Cancer Opportunity and Unmet Need Analysis, 2011
  • Figure 5: Novel Therapies in Oncology, Adjuvant Breast Cancer Opportunity and Unmet Need Analysis, 2011
  • Figure 6: Novel Therapies in Oncology, Colorectal Cancer Opportunity and Unmet Need Analysis, 2011
  • Figure 7: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, First-line Therapy, 2011
  • Figure 8: Novel Therapies in Oncology, NHL Opportunity and Unmet Need Analysis, Second line Therapy, 2011
  • Figure 9: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, First line Therapy, 2011
  • Figure 10: Novel Therapies in Oncology, NSCLC Opportunity and Unmet Need Analysis, Second Line Therapy, 2011
  • Figure 11: Novel Therapies in Oncology, Prostate Cancer Opportunity and Unmet Need Analysis, 2011
  • Figure 12: Novel Therapies in Oncology, Ovarian Cancer Opportunity and Unmet Need Analysis, 2011
  • Figure 13: Novel Therapies in Oncology, Cervical Cancer Opportunity and Unmet Need Analysis, 2011
  • Figure 14: Novel Therapies in Oncology, Head and Neck Cancer Opportunity and Unmet Need Analysis, 2011
  • Figure 15: Novel Therapies in Oncology, Pipeline by Developmental Phase (%), 2011
  • Figure 16: Novel Therapies in Oncology, Pipeline by Indication (%), 2011
  • Figure 17: Novel Therapies in Oncology, Pipeline by Therapeutic Class (%), 2011
  • Figure 18: Novel Therapies in Oncology, Breast Cancer Pipeline by Phase (%), 2011
  • Figure 19: Novel Therapies in Oncology, Breast Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 20: Novel Therapies in Oncology, Breast Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011
  • Figure 21: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 22: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 23: Novel Therapies in Oncology, Breast Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 24: Novel Therapies in Oncology, Colorectal Cancer Pipeline by Phase (%), 2011
  • Figure 25: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 26: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Discovery Molecules by Therapeutic Class (%), 2011
  • Figure 27: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 28: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 29: Novel Therapies in Oncology, Colorectal Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 30: Novel Therapies in Oncology, NHL Pipeline by Phase (%), 2011
  • Figure 31: Novel Therapies in Oncology, NHL Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 32: Novel Therapies in Oncology, NHL Pipeline, Discovery Molecules by Therapeutic Class (%), 2011
  • Figure 33: Novel Therapies in Oncology, NHL Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 34: Novel Therapies in Oncology, NHL Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 35: Novel Therapies in Oncology, NHL Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 36: Novel Therapies in Oncology, NSCLC Pipeline Molecules by Phase (%), 2011
  • Figure 37: Novel Therapies in Oncology, NSCLC Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 38: Novel Therapies in Oncology, NSCLC Pipeline, Discovery Molecules by Therapeutic Class (%), 2011
  • Figure 39: Novel Therapies in Oncology, NSCLC Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 40: Novel Therapies in Oncology, NSCLC Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 41: Novel Therapies in Oncology, NSCLC Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 42: Novel Therapies in Oncology, NSCLC Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011
  • Figure 43: Novel Therapies in Oncology, Prostate Cancer Pipeline Molecules by Phase (%), 2011
  • Figure 44: Novel Therapies in Oncology, Prostate Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 45: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 46: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 47: Novel Therapies in Oncology, Prostate Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 48: Novel Therapies in Oncology, Prostate Cancer Pipeline, NDA Filed Molecules by Therapeutic Class (%), 2011
  • Figure 49: Novel Therapies in Oncology, Ovarian Cancer Pipeline Molecules by Phase (%), 2011
  • Figure 50: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 51: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 52: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 53: Novel Therapies in Oncology, Ovarian Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 54: Novel Therapies in Oncology, Cervical Cancer Pipeline Molecules by Phase (%), 2011
  • Figure 55: Novel Therapies in Oncology, Cervical Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 56: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 57: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 58: Novel Therapies in Oncology, Cervical Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 59: Novel Therapies in Oncology, Head and Neck Cancer Pipeline Molecules by Phase (%), 2011
  • Figure 60: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Pre-Clinical Molecules by Therapeutic Class (%), 2011
  • Figure 61: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase I Molecules by Therapeutic Class (%), 2011
  • Figure 62: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase II Molecules by Therapeutic Class (%), 2011
  • Figure 63: Novel Therapies in Oncology, Head and Neck Cancer Pipeline, Phase III Molecules by Therapeutic Class (%), 2011
  • Figure 64: Novel Therapies in Oncology, T-DM1 Global Revenues ($m), 2013-2018
  • Figure 65: Novel Therapies in Oncology, Afinitor Global Revenues ($m), 2013-2018
  • Figure 66: Novel Therapies in Oncology, Iniparib Global Revenues ($m), 2015-2018
  • Figure 67: Novel Therapies in Oncology, Afatinib Global Revenues ($m), 2013-2018
  • Figure 68: Novel Therapies in Oncology, Avastin Global Revenues ($m), 2012-2018
  • Figure 69: Novel Therapies in Oncology, Farletuzumab Global Revenues ($m), 2014-2018
  • Figure 70: Novel Therapies in Oncology, V503 Global Revenues ($m), 2013-2018
  • Figure 71: Novel Therapies in Oncology, Tykerb Global Revenues ($m), 2014-2018
  • Figure 72: Novel Therapies in Oncology, Thera CIM Global Revenues ($m), 2015-2018
  • Figure 73: Novel Therapies in Oncology, Global, M&A Deals by Year, 2007-2011
  • Figure 74: Novel Therapies in Oncology, Global, M&A Deals by Geography, (%), 2007-2011
  • Figure 75: Novel Therapies in Oncology, Global, M&A Deals by Value, (%), 2007-2011
  • Figure 76: Novel Therapies in Oncology, Global, M&A Deals by Deal Type, (%), 2007-2011
  • Figure 77: Novel Therapies in Oncology, Global, R&D Licensing Deals by Year, 2007-2011
  • Figure 78: Novel Therapies in Oncology, Global, R&D Licensing Deals by Geography, (%), 2007-2011
  • Figure 79: Novel Therapies in Oncology, Global, R&D Licensing Deals by Value, (%), 2007-2011
  • Figure 80: Novel Therapies in Oncology, Global, Co-Development Deals by Year, 2007-2011
  • Figure 81: Novel Therapies in Oncology, Global, Co-Development Deals by Geography, (%), 2007-2011
  • Figure 82: Novel Therapies in Oncology, Global, Co-Development Deals by Value, (%), 2007-2011
Back to Top